AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Amyloid beta regulation == Neprilysin-deficient knockout mice show both Alzheimer's-like behavioral impairment and amyloid-beta deposition in the brain, providing strong evidence for the protein's association with the Alzheimer's disease process. Because neprilysin is thought to be the rate-limiting step in amyloid beta degradation, it has been considered a potential therapeutic target; compounds such as the peptide hormone somatostatin have been identified that increase the enzyme's activity level. Declining neprilysin activity with increasing age may also be explained by oxidative damage, known to be a causative factor in Alzheimer's disease; higher levels of inappropriately oxidized neprilysin have been found in Alzheimer's patients compared to cognitively normal elderly people.
the Emil Fischer Medal of the Society of German Chemists (1922), the Cannizaro Prize of the Royal Academy of Science in Rome (1938), the Copernicus Prize of the University of Konigsberg (1941), the Gothenius Medal of the Akademie der Naturforscher (1943), the Max Planck Medal of the German Physical Society, with Lise Meitner (1949), the Goethe Medal of the city of Frankfurt-on-the-Main (1949), the Golden Paracelsus Medal of the Swiss Chemical Society (1953), the Faraday Lectureship Prize with Medal from the Royal Society of Chemistry (1956), the Grotius Medal of the Hugo Grotius Foundation (1956), the Wilhelm Exner Medal of the Austrian Industry Association (1958), the Helmholtz Medal of the Berlin-Brandenburg Academy of Sciences and Humanities (1959), and the Harnack medal in Gold from the Max Planck Society (1959).
== Contraindications == Anyone who is unstable for surgery should not undergo flap surgery. As with most surgeries, people who are sicker may have more difficulties with wound healing. Comorbidities include diabetes, smoking, immunosuppression, and vascular disease.
=== Metabolic regulation === Enzyme inhibition is a common feature of metabolic pathway control in cells. Metabolic flux through a pathway is often regulated by a pathway's metabolites acting as inhibitors and enhancers for the enzymes in that same pathway. The glycolytic pathway is a classic example. This catabolic pathway consumes glucose and produces ATP, NADH and pyruvate. A key step for the regulation of glycolysis is an early reaction in the pathway catalysed by phosphofructokinase‑1 (PFK1). When ATP levels rise, ATP binds an allosteric site in PFK1 to decrease the rate of the enzyme reaction; glycolysis is inhibited and ATP production falls. This negative feedback control helps maintain a steady concentration of ATP in the cell. However, metabolic pathways are not just regulated through inhibition since enzyme activation is equally important. With respect to PFK1, fructose 2,6-bisphosphate and ADP are examples of metabolites that are allosteric activators. Physiological enzyme inhibition can also be produced by specific protein inhibitors. This mechanism occurs in the pancreas, which synthesises many digestive precursor enzymes known as zymogens. Many of these are activated by the trypsin protease, so it is important to inhibit the activity of trypsin in the pancreas to prevent the organ from digesting itself. One way in which the activity of trypsin is controlled is the production of a specific and potent trypsin inhibitor protein in the pancreas.
Sources: en.wikipedia.org
=== 8 March === EU ministers of defense agreed to purchase 1 billion euros worth of new artillery shells and provide another 1 billion euros worth of existing materials. Manufacturers needed larger orders to be financially secure enough to build new factories; new orders of artillery ammunition could take 2–3 years if produced using only the current factories. The US government was considering sending AIM-120 missiles to arm the Ukrainian Air Force's MiG-29 and Su-27.
==== Juvenile behavior ==== Juvenile blue tangs exhibit different behavior than both conspecific and congeneric adults. Juveniles are prevalent in the reef crest zone, spur zone, and on the fringe of the reef flat zone, but are rare inside of the reef flat zone. Juveniles remain solitary on their home ranges, and home range territory size increases with body size. These territories overlap with those of Stegastes damselfish. Juvenile blue tangs are aggressive in territory defense. They try to avoid Stegastes, and are rarely chased by these damselfish.
== Further reading == Ezzati M, Carr BR (January 2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi:10.2217/whe.14.68. PMID 25581052. Melis GB, Neri M, Corda V, Malune ME, Piras B, Pirarba S, Guerriero S, Orrù M, D'Alterio MN, Angioni S, Paoletti AM (May 2016). "Overview of elagolix for the treatment of endometriosis". Expert Opin Drug Metab Toxicol. 12 (5): 581–8. doi:10.1517/17425255.2016.1171316. PMID 27021205. S2CID 28684228. Alessandro P, Luigi N, Felice S, Maria PA, Benedetto MG, Stefano A (April 2017). "Research development of a new GnRH antagonist (Elagolix) for the treatment of endometriosis: a review of the literature". Arch. Gynecol. Obstet. 295 (4): 827–832. doi:10.1007/s00404-017-4328-6. PMID 28255765. S2CID 26422467. Perricos A, Wenzl R (September 2017). "Efficacy of elagolix in the treatment of endometriosis". Expert Opin Pharmacother. 18 (13): 1391–1397. doi:10.1080/14656566.2017.1359258. PMID 28737050. S2CID 32467159. Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K (July 2018). "Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies". Obstet Gynecol. 132 (1): 147–160. doi:10.1097/AOG.0000000000002675. PMID 29889764. Taylor HS (July 2018). "Use of Elagolix in Gynaecology".
Sources: en.wikipedia.org
At the October 1907 meeting of the American Roentgen Ray Society, Rome Vernon Wagner, an X-ray tube manufacturer, reported that he had begun carrying a photographic plate in his pocket and developing it every evening. This allowed him to determine how much radiation he had been exposed to. This was the forerunner of the film dosimeter. His efforts came too late, as he had already developed cancer and died six months after the conference. In the 1920s, the physical chemist John Eggert (1891-1973) played a key role in the introduction of film dosimetry for routine personal monitoring. Since then, it has been successively improved and, in particular, the evaluation technique has been automated since the 1960s. At the same time, Hermann Joseph Muller (1890-1967) discovered mutations as genetic consequences of X-rays, for which he was awarded the Nobel Prize in 1946. At the same time, the roentgen (R) was introduced as a unit for quantitative measurement of radiation exposure. A dosimeter for film is divided into multiple segments, each containing a light- or radiation-sensitive film surrounded by layers of copper and lead with varying thickness. The degree of radiation penetration determines whether the segment is not blackened or blackened to varying degrees. The absorbed radiation effect during the measurement time is summed up, and the radiation dose can be determined from the blackening. Guidelines for evaluation exist, with those for Germany being published in 1994 and last updated on December 8, 2003.
Mass cytometry is a high-dimensional single-cell analysis technique that integrates flow cytometry with time of flight mass spectrometry. It is used for the determination of the properties of cells (cytometry). In this approach, antibodies are conjugated with isotopically pure elements, and these antibodies are used to label cellular proteins. Cells are nebulized and sent through an argon plasma, which ionizes the metal-conjugated antibodies. The metal signals are then analyzed by a time-of-flight mass spectrometer. The approach overcomes limitations of spectral overlap in flow cytometry by utilizing discrete isotopes as a reporter system instead of traditional fluorophores which have broad emission spectra.
Cape Town ⟷ Kimberley ⟷ Johannesburg: General freight Durban ⟷ Richards Bay: Coastal freight Johannesburg ⟷ Durban: General freight (SA's busiest intermodal freight corridor) Johannesburg ⟷ Gqeberha / Ngqura: Automotive exports and manufactured goods Johannesburg ⟷ Polokwane: Mining supplies, and agricultural and manufacturing freight Johannesburg ⟷ Richards Bay: General freight Johannesburg ⟷ KuGompo City: Automotive and general freight Johannesburg ⟷ Komatipoort: Cross-border freight to Mozambique and the rest of the SADC Johannesburg ⟷ Beitbridge: Cross-border freight into Zimbabwe Johannesburg ⟷ Mahikeng / Ramatlabama: Cross-border freight into Botswana As of 2026, Transnet Freight Rail moves 17% of South Africa's freight annually, including 100% of its export coal and iron ore. The company coordinates its rail freight services with other Transnet divisions, such as ports, pipelines, and engineering. With over 25,000 employees, Transnet Freight Rail generates over R14 billion in annual revenue. For its 2025/2026 financial year, Transnet expected to transport a total rail cargo volume of around 168 million tons, up around 5%, from 160.1 million tons the year before. Under the South African Government's rail restructuring plan, the goal is for Transnet to reach a transport capacity of 185 million tons, with a further 65 million tons transported by private operators, by 2030. This would make for a total South African cargo rail capacity of 250 million tons per year.
The production of Champagne and many sparkling wines requires a second fermentation to occur in the bottle in order to produce the carbonation necessary for the style. A small amount of sugared liquid is added to individual bottles, and the yeast is allowed to convert this to more alcohol and carbon dioxide. The lees are then ricked into the neck of the bottle, frozen, and expelled via pressure of the carbonated wine.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.